loader
Please Wait
Applying Filters...
Close
4

M2i Group Roflumilast M2i Group Roflumilast

X

Annual Sales of 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Client Email Product
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 Daliresp/Daxas (1)

URL Supplier Web Content
Daliresp
Respiratory disorders
Euro
62
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp
Respiratory Disorders
USD
0
104
0
104
104
New Launch
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
154
104
154
104
50
48
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
198
154
198
154
44
29
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
189
198
189
198
-9
-5%
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
215
189
215
189
26
14
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
217
215
217
215
2
1
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Disorders
USD
227
217
227
217
10
5
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Diseases
USD
189
227
189
227
-38
-17
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
URL Supplier Web Content
Daliresp/Daxas
Respiratory Diseases
USD
54
189
54
189
-135
-71
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Post Enquiry
POST ENQUIRY